| 0.3672 Delayed Data As of 3:59pm ET |  -0.0128 / -3.37%Today’s Change | 0.35 Today|||52-Week Range 1.84 | -16.03% Year-to-Date |
| BioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade May 17 / Zacks.comZAK - Paid Partner Content |
| Previous close | 0.38 |
| Today’s open | 0.39 |
| Day’s range | 0.36 - 0.39 |
| Volume | 1,111,635 |
| Average volume (3 months) | 1,304,113 |
| Market cap | $53.5M |
| Earnings growth (last year) | +22.47% |
| Earnings growth (this year) | +19.05% |
| Earnings growth (next 5 years) | -25.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.03 |
| Today’s change | Today’s % change | |
|---|---|---|
| AVDLAvadel Pharmaceutica... | +0.04 | +2.68% |
| ISEEIVERIC bio Inc | 0.00 | 0.00% |
| --Innovative Pharmaceu... | +0.00 | +2.56% |
| SMMTSummit Therapeutics ... | -0.02 | -1.22% |
| Next reporting date | August 7, 2019 |
| EPS forecast (this quarter) | -$0.05 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$22.9M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chief Executive Officer Philip Adam Serlin |
Chief Financial Officer Mali Zeevi |
Corporate headquarters Modi'in, Tel Aviv |
